Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmet Yildirim

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
JCO Global Oncology|October 29, 2025
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 StudyFrancesco Massari, Matteo Rosellini, Bohuslav Melichar, et al.
Cancer Immunology, Immunotherapy : CII|November 14, 2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 studyRay Manneh Kopp, Francesco Massari, Enrique Grande, et al.
European Urology Focus|July 30, 2025
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 StudyFrancesco Massari, Veronica Mollica, Ray Manneh Kopp, et al.
Frontiers in Pediatrics|July 18, 2022
Increased Severe Cases and New-Onset Type 1 Diabetes Among Children Presenting With Diabetic Ketoacidosis During First Year of COVID-19 Pandemic in TurkeyEylem Kiral, Birgul Kirel, Merve Havan, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
JCO Global Oncology|October 29, 2025
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 StudyFrancesco Massari, Matteo Rosellini, Bohuslav Melichar, et al.
Cancer Immunology, Immunotherapy : CII|November 14, 2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 studyRay Manneh Kopp, Francesco Massari, Enrique Grande, et al.
European Urology Focus|July 30, 2025
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 StudyFrancesco Massari, Veronica Mollica, Ray Manneh Kopp, et al.
Frontiers in Pediatrics|July 18, 2022
Increased Severe Cases and New-Onset Type 1 Diabetes Among Children Presenting With Diabetic Ketoacidosis During First Year of COVID-19 Pandemic in TurkeyEylem Kiral, Birgul Kirel, Merve Havan, et al.
Pageof 9